FDA Approvals Signal Shift Towards Convenience-Driven Patient Care

Recent FDA approvals, including an allogeneic regulatory T cell–based immunotherapy for stem cell transplants, the first oral PCSK9 inhibitor for high cholesterol (enlicitide), and a new option for ROS1-positive non–small cell lung cancer (zidesamtinib), highlight a growing trend towards therapies that offer greater convenience for patients. These approvals, occurring between July 1 and July 24, 2026, aim to reduce the burden of infusions, injections, or hospital visits by providing oral medications, at-home autoinjectors, or better-tolerated regimens.